The Role of Interleukin-6/GP130 Signaling in Prostate Cancer Progression and its Contribution to Bone Metastasis Morbidity
Final rept. 1 Mar 2006-15 Oct 2008
MONASH UNIV CLAYTON (AUSTRALIA) INST OF MEDICAL RESEARCH
Pagination or Media Count:
Prostate cancer PrCa is the leading cause of male cancer death in Western civilization. Interleukin-6 IL-6 is a cytokine implicated in primary PrCa growth and survival post-androgen withdrawal. Moreover, IL-6 is strongly associated with bone metastasis, a major cause of morbidity in PrCa patients. This project aims to investigate the IL-6 axis in a novel in vivo PrCa xenograft model BM18 of androgen-dependent growth McCulloch et al., 2005 and osteosclerotic bone metastasis. The IL- 6gp130 signaling pathway was also investigated using PrCa bone metastases from human patient biopsies. Pursuit of the aims outlined herein will greatly improve our understanding of the role of IL- 6gp130 signaling in prostate cancer growth, regression, survival post-androgen withdrawal and bone metastasis. This study provides a unique opportunity to examine the role of IL-6gp130 signaling in a model that closely mimics human PrCa growth, progression and regression as well as osteosclerotic bone remodeling. Disease recurrence and osteosclerotic metastases are poorly understood processes that cause immense suffering, culminating in a painful demise. Understanding the role of IL-6gp130 signaling molecules in this disease may lead to identification of novel targets and therapeutic strategies to improve and extend the quality of life for PrCa patients.
- Anatomy and Physiology
- Medicine and Medical Research